BeOne Medicines anchors itself in the Basel Area
By choosing Basel as its new headquarters, BeOne Medicines is sending out a strong signal. The region will become a global hub for oncological innovation. The decision underlines the international appeal of the Basel Area as a leading life sciences location and accelerates the growth of one of the world's most promising oncology companies.
BeOne Medicines, formerly BeiGene, has officially relocated its headquarters to Switzerland. Already present in Basel since 2018, the global oncology company is now permanently anchored in the heart of one of Europe’s most innovative biotech hotspots. Basel not only boasts more than 30,000 highly qualified life sciences specialists, but also excellent conditions for regulatory cooperation and international networking.
Strategic impetus for research and development
BeOne pursues a vertically integrated innovation strategy that combines basic research, clinical development and production under one roof. The company has one of the most extensive oncology pipelines in the world. With more than 50 investigational compounds, including a BTK inhibitor already approved in 75 countries, BeOne addresses both hematological diseases and solid tumors. Development is based on future technologies such as multispecific antibodies and protein degradation products.
Site selection as part of a global expansion strategy
The Basel Area will thus become the European hub of BeOne’s clinical activities. As early as 2024, 13 new drug candidates were transferred to clinical trials. A peak value even compared to Big Pharma. More than 40 trials are currently underway in Europe, involving over 3,000 patients. BeOne employs more than 11,000 people worldwide on six continents, with a rapidly growing proportion in Switzerland.
A gain for the location and for investors
For Basel as a location, BeOne’s decision means a clear gain in international visibility, jobs and investment momentum. For investors and project developers in the life sciences, there are new opportunities along the entire value chain, from laboratory space to clinical study centers and production. The proximity to science, talent and regulatory authorities creates ideal conditions for further growth.